DGAP-News: Westhouse Medical Services Plc. acquires revolutionary glaucoma treatment and device patents from US Quoted Company, Sunridge International
(firmenpresse) - DGAP-News: Westhouse Medical Services plc / Key word(s): Acquisition
Westhouse Medical Services Plc. acquires revolutionary glaucoma
treatment and device patents from US Quoted Company, Sunridge
International
17.04.2012 / 07:00
---------------------------------------------------------------------
Westhouse Medical Services Plc. acquires revolutionary glaucoma treatment
and device patents from US Quoted Company, Sunridge International
LONDON, UK, 17th April 2012 - Healthcare specialist Westhouse Medical
Services Plc. ('Ticker Symbol 5WM') today announces it has entered into a
$2,000,000 cash and bond deal to acquire assets of Sunridge International.
Sunridge will deliver the patents, manufacturing rights, distribution
agreements and intellectual property for Pneumatic Trabeculoplasty (PNT) -
the method of treatment and equipment used to treat glaucoma and ocular
hypertension.
The acquisition gives Westhouse Medical Services direct access to the US
healthcare market. This is of strategic importance as Westhouse prepare to
launch BreastCheck - a revolutionary, non-invasive, breast cancer scanning
device which could act as a pre-cursor to the mammogram. The patented and
FDA approved BreastCheck product is set for release in summer 2012.
Westhouse is proactively looking to expand its two subsidiaries - Devices
and Services - and the acquisition of PNT as a ground-breaking new medical
product will enhance the company's devices portfolio.
PNT is the only non-invasive method of treatment capable of reducing
intra-occular pressure in sufferers of Primary Open Angle Glaucoma (POAG) -
which accounts for 95% of diagnosed glaucoma cases in Europe, the Americas
and Africa - as well as ocular hypertension. PNT stimulates a drop in eye
pressure, diminishing the need for drug-related treatment in most patients.
Westhouse CEO, Jack Kaye, comments: 'Through this acquisition Westhouse
will be able to improve the standards of care, and quality of life, for the
world's 67 million glaucoma sufferers, as well as lowering overall
treatment costs. This maintains Westhouse's commitment to improving primary
healthcare, while creating value for investors, healthcare providers and
patients alike.'
The Sunridge acquisition represents further growth of Westhouse's Services
subsidiary. This will be the second addition following the purchase of
Profemme's UK and US breast cancer screening patents in November 2011.
WESTHOUSE MEDICAL SERVICES PLC
SYMBOL: 5WM
WKN: A1JKH7
ISIN: GB00B6YWDK49
SEDOL: B6YWDK4
~ends~
For press information, contact:
Jo Lee / Sian Edwards/ George Baggaley
Chameleon PR
Email: westhouse(at)chameleonpr.com
Ph: +44 (0) 207 680 5500
End of Corporate News
---------------------------------------------------------------------
17.04.2012 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
165163 17.04.2012
Themen in dieser Pressemitteilung:
westhouse-medical-services-plc-acquires-revolutionary-glaucoma-treatment-and-device-patents-from-us-quoted-company
sunridge-international
Unternehmensinformation / Kurzprofil:
Datum: 17.04.2012 - 07:00 Uhr
Sprache: Deutsch
News-ID 135535
Anzahl Zeichen: 6106
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 199 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Westhouse Medical Services Plc. acquires revolutionary glaucoma treatment and device patents from US Quoted Company, Sunridge International"
steht unter der journalistisch-redaktionellen Verantwortung von
Westhouse Medical Services plc (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
